Research Analysts Offer Predictions for BSX FY2025 Earnings

Boston Scientific Corporation (NYSE:BSX) – Equities researchers at Leerink Partnrs issued their FY2025 earnings per share (EPS) estimates for Boston Scientific in a report released on Monday, June 16th. Leerink Partnrs analyst M. Kratky anticipates that the medical equipment provider will earn $2.93 per share for the year. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Boston Scientific’s current full-year earnings is $2.85 per share. Leerink Partnrs also issued estimates for Boston Scientific’s FY2028 earnings at $4.32 EPS and FY2029 earnings at $4.79 EPS.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.08. The business had revenue of $4.66 billion during the quarter, compared to the consensus estimate of $4.57 billion. Boston Scientific had a return on equity of 18.67% and a net margin of 11.58%. The company’s revenue was up 20.9% compared to the same quarter last year. During the same period in the prior year, the company earned $0.56 earnings per share.

Several other research firms also recently weighed in on BSX. Truist Financial increased their price objective on Boston Scientific from $113.00 to $117.00 and gave the company a “buy” rating in a report on Thursday, April 24th. Erste Group Bank raised Boston Scientific to a “strong-buy” rating in a report on Thursday, May 8th. Royal Bank Of Canada increased their price objective on Boston Scientific from $116.00 to $120.00 and gave the company an “outperform” rating in a report on Thursday, April 24th. Wall Street Zen upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a research report on Tuesday, April 29th. Finally, Barclays lifted their price objective on shares of Boston Scientific from $118.00 to $125.00 and gave the company an “overweight” rating in a research report on Friday, April 25th. Twenty-two investment analysts have rated the stock with a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $116.09.

Boston Scientific Price Performance

BSX stock opened at $101.72 on Wednesday. The company has a market capitalization of $150.49 billion, a P/E ratio of 74.25, a PEG ratio of 2.62 and a beta of 0.68. Boston Scientific has a twelve month low of $71.88 and a twelve month high of $107.17. The business has a 50 day simple moving average of $101.35 and a 200-day simple moving average of $98.89. The company has a current ratio of 1.45, a quick ratio of 0.88 and a debt-to-equity ratio of 0.47.

Insider Buying and Selling at Boston Scientific

In other news, EVP John Bradley Sorenson sold 4,572 shares of Boston Scientific stock in a transaction on Monday, May 5th. The stock was sold at an average price of $104.54, for a total transaction of $477,956.88. Following the completion of the transaction, the executive vice president now owns 18,705 shares of the company’s stock, valued at $1,955,420.70. The trade was a 19.64% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 56,372 shares of Boston Scientific stock in a transaction on Wednesday, June 4th. The stock was sold at an average price of $102.88, for a total value of $5,799,551.36. Following the transaction, the executive vice president now directly owns 178,342 shares of the company’s stock, valued at $18,347,824.96. This trade represents a 24.02% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 411,970 shares of company stock valued at $42,406,693. 0.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Parnassus Investments LLC raised its stake in shares of Boston Scientific by 0.7% during the 4th quarter. Parnassus Investments LLC now owns 14,861 shares of the medical equipment provider’s stock worth $1,327,000 after buying an additional 97 shares during the last quarter. HM Payson & Co. raised its stake in shares of Boston Scientific by 1.4% during the 1st quarter. HM Payson & Co. now owns 6,875 shares of the medical equipment provider’s stock worth $694,000 after buying an additional 98 shares during the last quarter. Baldwin Investment Management LLC raised its stake in Boston Scientific by 1.2% in the 4th quarter. Baldwin Investment Management LLC now owns 8,740 shares of the medical equipment provider’s stock valued at $781,000 after purchasing an additional 102 shares during the last quarter. Park Square Financial Group LLC raised its stake in Boston Scientific by 5.2% in the 1st quarter. Park Square Financial Group LLC now owns 2,066 shares of the medical equipment provider’s stock valued at $208,000 after purchasing an additional 103 shares during the last quarter. Finally, HHM Wealth Advisors LLC raised its stake in Boston Scientific by 13.2% in the 1st quarter. HHM Wealth Advisors LLC now owns 881 shares of the medical equipment provider’s stock valued at $89,000 after purchasing an additional 103 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.